GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Sleep apnea and cardiovascular diseases
Breathless through the night
- Diagnostics, differentiation and multimodal therapy
Vulvar diseases and vulvodynia
- From symptom to diagnosis
Abdominal pain – Prostate lipoma
- Acute pulmonary embolism: new AHA/ACC guideline
Practical recommendations for risk-stratified triage
- Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology
Lp(a): The underestimated risk factor before the turning point
- Modern system therapeutics for hidradenitis suppurativa
Immunological dysregulation in the sights of several biologics and “small molecules”
- Perimenopausal depression, PMDS and tokophobia
Psychosomatics and mental health in gynecology
- Plastic surgery and reconstructive microsurgery for DFS